Literature DB >> 16127750

Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.

Laura Peran1, Desiree Camuesco, Monica Comalada, Ana Nieto, Angel Concha, Maria Paz Diaz-Ropero, Monica Olivares, Jordi Xaus, Antonio Zarzuelo, Julio Galvez.   

Abstract

AIM: To investigate the intestinal anti-inflammatory effect and mechanism of a probiotic Lactobacillus salivarius ssp. salivarius CECT5713 in the TNBS model of rat colitis.
METHODS: Female Wistar rats (180-200 g) were used in this study. A group of rats were administered orally the probiotic L. salivarius ssp. salivarius (5x10(8) CFU suspended in 0.5 mL of skimmed milk) daily for 3 wk. Two additional groups were used for reference, a non-colitic and a control colitic without probiotic treatment, which received orally the vehicle used to administer the probiotic. Two weeks after starting the experiment, the rats were rendered colitic by intracolonic administration of 10 mg of TNBS dissolved in 0.25 mL of 500 mL/L ethanol. One week after colitis induction, all animals were killed and colonic damage was evaluated both histologically and biochemically. The biochemical studies performed in colonic homogenates include determination of myeloperoxidase (MPO) activity, glutathione (GSH) content, leukotriene B4 (LTB4) and tumor necrosis factor alpha (TNF-alpha) levels, as well as inducible nitric oxide synthase (iNOS) expression. In addition, the luminal contents obtained from colonic samples were used for microbiological studies, in order to determine Lactobacilli and Bifidobacteria counts.
RESULTS: Treatment of colitic rats with L. salivarius ssp. salivarius resulted in amelioration of the inflammatory response in colitic rats, when compared with the corresponding control group without probiotic treatment. This anti-inflammatory effect was evidenced macroscopically by a significant reduction in the extent of colonic necrosis and/or inflammation induced by the administration of TNBS/ethanol (2.3+/-0.4 cm vs 3.4+/-0.3 cm in control group, P<0.01) and histologically by improvement of the colonic architecture associated with a reduction in the neutrophil infiltrate in comparison with non-treated colitic rats. The latter was confirmed biochemically by a significant reduction of colonic MPO activity (105.3+/-26.0 U/g vs 180.6+/-21.9 U/g, P<0.05), a marker of neutrophil infiltration. The beneficial effect was associated with an increase of the colonic GSH content (1252+/-42 nmol/g vs 1087+/-51 nmol/g, P<0.05), which is depleted in colitic rats, as a consequence of the oxidative stress induced by the inflammatory process. In addition, the treatment of colitic rats with L. salivarius resulted in a significant reduction of colonic TNF-alpha levels (509.4+/-68.2 pg/g vs 782.9+/-60.1 pg/g, P<0.01) and in a lower colonic iNOS expression, when compared to TNBS control animals without probiotic administration. Finally, treated colitic rats showed higher counts of Lactobacilli species in colonic contents than control colitic rats, whereas no differences were observed in Bifidobacteria counts.
CONCLUSION: Administration of the probiotic L. salivarius ssp. salivarius CECT5713 facilitates the recovery of the inflamed tissue in the TNBS model of rat colitis, an effect associated with amelioration of the production of some of the mediators involved in the inflammatory response in the intestine, such as cytokines, including TNF-alpha and NO. This beneficial effect could be ascribed to its effect on the altered immune response that occurs in this inflammatory condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127750      PMCID: PMC4320393          DOI: 10.3748/wjg.v11.i33.5185

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  53 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease.

Authors:  S J McKenzie; M S Baker; G D Buffinton; W F Doe
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  Incrimination of anaerobic bacteria in the induction of experimental colitis.

Authors:  A García-Lafuente; M Antolín; F Guarner; E Crespo; A Salas; P Forcada; M Laguarda; J Gavaldá; J A Baena; J Vilaseca; J R Malagelada
Journal:  Am J Physiol       Date:  1997-01

4.  Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism.

Authors:  Jeremy Andrew Peña; James Versalovic
Journal:  Cell Microbiol       Date:  2003-04       Impact factor: 3.715

5.  Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease.

Authors:  H Kimura; S Miura; T Shigematsu; N Ohkubo; Y Tsuzuki; I Kurose; H Higuchi; Y Akiba; R Hokari; M Hirokawa; H Serizawa; H Ishii
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

6.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function.

Authors:  K Madsen; A Cornish; P Soper; C McKaigney; H Jijon; C Yachimec; J Doyle; L Jewell; C De Simone
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

7.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; J S Kenney; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

8.  Distribution of inducible nitric oxide synthase in ulcerative colitis.

Authors:  I Ikeda; T Kasajima; S Ishiyama; T Shimojo; Y Takeo; T Nishikawa; S Kameoka; M Hiroe; A Mitsunaga
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

9.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

10.  PKC epsilon is involved in JNK activation that mediates LPS-induced TNF-alpha, which induces apoptosis in macrophages.

Authors:  Mònica Comalada; Jordi Xaus; Annabel F Valledor; Carlos López-López; Daniel J Pennington; Antonio Celada
Journal:  Am J Physiol Cell Physiol       Date:  2003-07-16       Impact factor: 4.249

View more
  45 in total

Review 1.  Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa.

Authors:  Peter A Bron; Peter van Baarlen; Michiel Kleerebezem
Journal:  Nat Rev Microbiol       Date:  2011-11-21       Impact factor: 60.633

Review 2.  Redox biology of the intestine.

Authors:  Magdalena L Circu; Tak Yee Aw
Journal:  Free Radic Res       Date:  2011-09-05

3.  Immunomodulatory activity of two potential probiotic strains in LPS-stimulated HT-29 cells.

Authors:  Raj Kumar Duary; Virender Kumar Batish; Sunita Grover
Journal:  Genes Nutr       Date:  2014-03-30       Impact factor: 5.523

Review 4.  Probiotics and prebiotics in chronic inflammatory bowel diseases.

Authors:  Julia B Ewaschuk; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

5.  Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.

Authors:  Benoit Foligne; Sophie Nutten; Corinne Grangette; Véronique Dennin; Denise Goudercourt; Sabine Poiret; Joelle Dewulf; Dominique Brassart; Annick Mercenier; Bruno Pot
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

6.  Promising immunomodulatory effects of selected strains of dairy propionibacteria as evidenced in vitro and in vivo.

Authors:  Benoît Foligné; Stéphanie-Marie Deutsch; Jérôme Breton; Fabien J Cousin; Joëlle Dewulf; Michel Samson; Bruno Pot; Gwénaël Jan
Journal:  Appl Environ Microbiol       Date:  2010-10-22       Impact factor: 4.792

Review 7.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

8.  Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis.

Authors:  Federico Lara-Villoslada; Oscar de Haro; Desire Camuesco; Mónica Comalada; Javier Velasco; Antonio Zarzuelo; Jordi Xaus; Julio Galvez
Journal:  Eur J Nutr       Date:  2006-07-26       Impact factor: 5.614

9.  Safety evaluation of Lactobacillus paracasei subsp. paracasei LC-01, a probiotic bacterium.

Authors:  Hao Zhang; Yu Wang; Jing Sun; Zirui Guo; Huiyuan Guo; Fazheng Ren
Journal:  J Microbiol       Date:  2013-10-31       Impact factor: 3.422

10.  Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease.

Authors:  Linda M Feighery; Philip Smith; Liam O'Mahony; Padraic G Fallon; David J Brayden
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.